NSE: TORNTPHARM | BSE: 500420

Expensive Performer

Download real time

3579.10 -20.20 (-0.56%)

95,438 NSE+BSE Volume

NSE 05 Sep, 2025 3:31 PM (IST)

121,133

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Torrent Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for TORNTPHARM, BSE:500420 Torrent Pharmaceuticals Ltd.

Torrent Pharmaceuticals Ltd.

01 Aug 2017

3579.10

-0.56%

Torrent Pharma (1QFY18): Margin beat. Maintain BUY

Buy: Torrent Pharmaceuticals Ltd.

Target

HDFC Securities

Maintain BUY with a TP of Rs 1,450 (20x Jun-19E). Despite a 9% decline in the India business, sequentially flat sales in the US and strong rupee appreciation during the last quarter, Torrent Pharma (TRP) reported 100bps QoQ improvement in EBITDA margin (21.6%) and 500bps higher gross margin, leading to a PAT of Rs 1.8bn (57% beat on our earnings estimates). Management has attributed this to the improved product mix in the US and Brazil markets, and price hikes in the India business.

Torrent Pharmaceutic.. has an average target of 3746.00 from 5 brokers.

Torrent Pharmaceuticals Ltd.

01 Aug 2017

3579.10

-0.56%

Torrent Pharmaceuticals

Hold: Torrent Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Revenues declined 11% YoY to | 1374 crore (I-direct estimate: | 1421 crore) mainly due to high base of gAbilify exclusivity in the US. US revenue declined 37% YoY to | 272 crore (I-direct estimate: | 261 crore). Domestic revenue declined 9% YoY to | 464 crore (Idirect estimate: | 428 crore) mainly due to GST transition EBITDA margins declined to 21.6% (I-direct estimate: 20.0%) against 28.3% in Q1FY17. EBITDA fell 32% YoY to | 297 crore Net profit fell 36% YoY to | 188 crore (I-direct estimate: | 164 crore) mainly on account of lower operational performance...

Torrent Pharmaceuticals Ltd. is trading below its 30 day SMA of 3623.7

Torrent Pharmaceuticals Ltd.

01 Aug 2017

3579.10

-0.56%

Result Review of Torrent Pharmaceuticals

Accumulate: Torrent Pharmaceuticals Ltd.

IDBI Capital

Q1FY18 revenues were down 10.9% YoY lower than our forecast by 4.6%. EBITDA margin of 20.1% were lower than our estimates of 20.5%, mainly on the back of increased staff and other expenses. However, PAT of Rs1.88bn, -35.6% YoY, was 8.5% lower than our estimates given higher tax rate. India business traction a little slower owing to GST and slower-than-expected pickup from Novartis brands, 8-10 launches in US and volume growth in Brazil to...

Torrent Pharmaceutic.. has an average target of 3746.00 from 5 brokers.

Torrent Pharmaceuticals Ltd.

24 Jun 2017

3579.10

-0.56%

Company Update of Torrent Pharmaceuticals

Accumulate: Torrent Pharmaceuticals Ltd.

Target

IDBI Capital

US contribution continues to reduce owing to the pricing pressure in the base business and lower FTF launches. In FY17, TRP filed 17 ANDAs of which 6 were FTFs. Focus on filings in specialty segments like dermatology, oncology and ophthalmology will help sustain EBIDTA. About 5-6 pending launches and with 10-12 launches every year in FY18/19E we estimate US...

Torrent Pharmaceuticals Ltd. is trading below its 30 day SMA of 3623.7

Torrent Pharmaceuticals Ltd.

29 May 2017

3579.10

-0.56%

Torrent Pharmaceuticals Ltd Q4FY17 results comment

Results Update: Torrent Pharmaceuticals Ltd.

HDFC Securities

Revenue fell by 2.26% to Rs. 1381.0 Cr in Q4FY17 when compared to the previous quarter.

Number of FII/FPI investors increased from 913 to 923 in Jun 2025 qtr.

Torrent Pharmaceuticals Ltd.

29 May 2017

3579.10

-0.56%

Torrent Pharma (4QFY17): US drags 4Q. Maintain BUY

Buy: Torrent Pharmaceuticals Ltd.

Target

HDFC Securities

Significantly low contribution from gAbilify, pricing pressure in Nexium and some older products, led to 45% YoY decline in Torrent Pharma?s (TRP) US sales in 4QFY17. This resulted in a low EBITDA margin of 20.6% and PAT decline of ~28% to ~Rs 2bn. However, TRP has filed six more ANDAs in 4QFY17, totalling 17 in FY17. Notably, these include two in derma and six FTFs. TRP?s pipeline build-up programme is likely to gain further momentum in FY18/FY19.

Number of FII/FPI investors increased from 913 to 923 in Jun 2025 qtr.

Torrent Pharmaceuticals Ltd.

29 May 2017

3579.10

-0.56%

Torrent Pharmaceuticals

Hold: Torrent Pharmaceuticals Ltd.

Recommendation Target

ICICI Securities Limited

Number of FII/FPI investors increased from 913 to 923 in Jun 2025 qtr.

Torrent Pharmaceuticals Ltd.

06 Feb 2017

3579.10

-0.56%

Torrent Pharmaceuticals Ltd Q3FY17 results comment

Results Update: Torrent Pharmaceuticals Ltd.

HDFC Securities

Revenue grew by 0.5% to Rs. 1413.0 Cr in Q3FY17 when compared to the previous quarter. On the other hand, it decreased by 6.92% when compared with Q3FY16.

Torrent Pharmaceutic.. has an average target of 3746.00 from 5 brokers.

Torrent Pharmaceuticals Ltd.

06 Feb 2017, 08:33AM

3579.10

-0.56%

Torrent Pharma (3QFY17): Pipeline build up continues. Maintain BUY

Buy: Torrent Pharmaceuticals Ltd.

Target

HDFC Securities

With 4 more filings in 3QFY17, TRP has now filed 10 ANDAs in the US on YTD basis and is on track to meet its earlier guidance of 15 filings in FY17. Notably, these filings include 2 derma and 2 FTFs. TRP?s pipeline build up program is likely to gain more momentum in FY18/FY19 with 40-45 filings over two years.

Sharekhan decreased Buy price target of Torrent Pharmaceuticals Ltd. to 4024.0 on 29 Aug, 2025.

Is Torrent Pharmaceuticals Ltd. worth buying?

155 Votes:

Buy 74.19%

Sell 16.77%

Hold 9.03%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf